VERICI DX PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.25 GBX | -3.85% |
|
-7.41% | -35.90% |
| 06-18 | EARNINGS AND TRADING: Cordel thrilled by Middle East contract win | AN |
| 06-18 | Verici Dx plc Announces Successful Transfer of Urine Samples to Thermo Fisher Scientific | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -35.90% | 19.9M | - | ||
| -10.34% | 11.57B | B+ | ||
| -12.48% | 7.37B | B- | ||
| +28.16% | 5.44B | C | ||
| +0.26% | 5.31B | B | ||
| -18.68% | 3.74B | C | ||
| +7.43% | 2.58B | - | - | |
| -65.12% | 2.33B | D+ | ||
| +26.59% | 2.23B | C | ||
| -11.15% | 2.21B | B- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- VRCI Stock
- Ratings Verici Dx plc
